4 out of 5 biopharmaceuticals increased exports

Samsung Biologics’ exports of 2.8 trillion won last year, a 2.3-fold increase in 1 year due to corona vaccine and CDMO orders

Celltrion's annual export performance is 2 trillion won

24 out of 30 listed pharmaceuticals, ↑ Exports

Annual exports of individual pharmaceutical bio companies exceeded 2 trillion won.

 

Last year, Samsung BioLogics recorded exports of 2.8 trillion won, up 2.3 times from the previous year, and Celltrion is also on the verge of achieving 2 trillion won.

 

Of the 30 major listed biopharmaceutical companies, 24 showed an increase in export performance compared to the previous year.

 

In addition to Samsung Biologics and Celltrion, ST Pharm, Ildong Pharm, Handok, HK Inno.N, and Daewoong are on the rise.

 

According to the Financial Supervisory Service on the 3rd, the export performance of 30 major listed pharmaceutical companies in Korea last year was 7.3188 trillion won.

 

Compared to 5.1946 trillion won in 2020, it increased by 37.4%.

 

Exports of domestic biopharmaceutical companies increased significantly in the course of the prolonged COVID-19 crisis.

 

In 2020, the first year of Corona, the exports of 30 companies were 3,989.8 billion won 2020, exceeding 5 trillion won the following year and 7 trillion won last year, respectively.

 

The increase in the export performance of Samsung Biologics is remarkable.

 

Samsung BioLogics' annual exports increased from 494.5 billion won in 2019 to 868.2 billion won in 2020 and 1.22 trillion won in 2021.

 

Last year, the scale of exports reached 2.2 trillion 846.6 billion won, and the rate of increase was even steeper.

 

It is an analysis that the company's exports have also increased significantly as the corona vaccine, which was consigned in earnest in 2021, was exported last year.

 

In addition to the corona vaccine, export performance has increased significantly as the volume of biopharmaceutical CDMO has steadily increased.

 

It is analyzed that the incorporation of Samsung Bioepis into a 100% subsidiary also contributed significantly to the expansion of export performance.

 

The increase in Samsung Biologics' exports directly contributed to the company's record-high sales.

 

Samsung BioLogics recorded sales of 3.13 trillion won last year, 94.8% of which came from exports.

 

Sales of Samsung Biologics were 2.8 trillion won and sales of Celltrion were 2 trillion won, last year’s record-breaking export performance.

 

By region, exports to Europe increased by 137% from 753.8 billion won to 1.7859 trillion won, and exports to North America increased by 90% from 448.6 billion won to 854 billion won.

 

Exports to other regions other than North America and Europe also stood at 19.3 billion won in 2020, but increased more than 10 times to 206.7 billion won last year.

 

Celltrion Healthcare also set a record high with exports of just under 2 trillion won.

 

Celltrion exports biosimilars around the world through its affiliate Celltrion Healthcare.

 

The company's exports last year were 1,964.7 billion won, up 9.0% from 1,802.9 billion won in 2021.

 

◆ Last year, 4 out of 5 listed pharmaceutical companies increased their export performance Of the 30 companies surveyed, 24 companies, excluding 6, increased their exports 4 out of 5 pharmaceutical companies saw their export performance improve.

 

In particular, Samsung Biologics, Ildong Pharmaceutical, Handok, HK Inno.N, and Daewoong Pharmaceutical showed an increase of more than 50% compared to the previous year.

 

One company that might be of interest is ST Pharm.

 

ST Pharm's exports last year were 218.4 billion won, up 68.3% from 129.8 billion won in 2021.

 

Among the 30 companies surveyed, exports are the sixth highest.

 

Only Samsung Biologics, Celltrion, GC Pharma, SK Biopharm, and SK Bioscience recorded higher exports than ST Pharm.

 

ST Pharm's export performance has been steadily increasing since 2019.

 

The company's exports, which stood at 46 billion won in 2019, increased by 1.6 to 1.7 times each year over the past four years, to 79.6 billion won in 2020, 129.8 billion won in 2021, and 218.4 billion won last year.

 

It is an analysis that the oligonucleotide drug substance business, which the company has taken as a new growth engine, is cruising.

 

The share of new drug APIs in the company's exports is increasing year by year.

 

In 2019, exports of new drug APIs were 24.7 billion won, accounting for only 53.7% of total exports.

 

Last year, exports of new drug APIs reached 172.2 billion won, a nearly seven-fold increase in three years.

 

The share of total exports also increased by 25.1%p over the past three years to 78.8%.